High Mobility Group Protein Box-1 (HMGB1) - Pipeline Review, H1 2016

  • ID: 3743745
  • Drug Pipelines
  • 40 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Affibody AB
  • Bio3 Research S.r.l
  • Evec, Inc.
  • Ribomic Inc.
  • MORE
High Mobility Group Protein Box-1 (HMGB1) - Pipeline Review, H1 2016

Summary

‘High Mobility Group Protein Box-1 (HMGB1) - Pipeline Review, H1 2016’, provides in depth analysis on High Mobility Group Protein Box-1 (HMGB1) targeted pipeline therapeutics.

The report provides comprehensive information on the High Mobility Group Protein Box-1 (HMGB1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in High Mobility Group Protein Box-1 (HMGB1) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for High Mobility Group Protein Box-1 (HMGB1)
- The report reviews High Mobility Group Protein Box-1 (HMGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in High Mobility Group Protein Box-1 (HMGB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses High Mobility Group Protein Box-1 (HMGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to High Mobility Group Protein Box-1 (HMGB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for High Mobility Group Protein Box-1 (HMGB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding High Mobility Group Protein Box-1 (HMGB1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Affibody AB
  • Bio3 Research S.r.l
  • Evec, Inc.
  • Ribomic Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

High Mobility Group Protein Box-1 (HMGB1) Overview

Therapeutics Development

High Mobility Group Protein Box-1 (HMGB1) - Products under Development by Stage of Development

High Mobility Group Protein Box-1 (HMGB1) - Products under Development by Therapy Area

High Mobility Group Protein Box-1 (HMGB1) - Products under Development by Indication

High Mobility Group Protein Box-1 (HMGB1) - Pipeline Products Glance

Early Stage Products

High Mobility Group Protein Box-1 (HMGB1) - Products under Development by Companies

High Mobility Group Protein Box-1 (HMGB1) - Products under Development by Universities/Institutes

High Mobility Group Protein Box-1 (HMGB1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

High Mobility Group Protein Box-1 (HMGB1) - Companies Involved in Therapeutics Development

Affibody AB

Bio3 Research S.r.l

Evec, Inc.

Ribomic Inc.

High Mobility Group Protein Box-1 (HMGB1) - Drug Profiles

Antibodies to Antagonize HMGB-1 for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTR-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTR-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTR-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTR-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EV-007156 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit HMGB1 for Brain Infarction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit HMGB1 for Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

High Mobility Group Protein Box-1 (HMGB1) - Dormant Projects

High Mobility Group Protein Box-1 (HMGB1) - Featured News & Press Releases

Nov 16, 2012: Bio3 Research Receives Hong Kong Patent For HMGB1 Antibodies To Treat Vascular Diseases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Affibody AB, H1 2016

Pipeline by Bio3 Research S.r.l, H1 2016

Pipeline by Evec, Inc., H1 2016

Pipeline by Ribomic Inc., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Affibody AB
  • Bio3 Research S.r.l
  • Evec, Inc.
  • Ribomic Inc.
  • MORE
High Mobility Group Protein Box-1 (HMGB1) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report High Mobility Group Protein Box-1 (HMGB1) – Pipeline Review, H1 2016, outlays comprehensive information on the High Mobility Group Protein Box-1 (HMGB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

High Mobility Group Protein Box-1 (HMGB1) High mobility group box 1 protein also known as high-mobility group protein 1 (HMG-1) is a protein encoded by the HMGB1 gene.HMGB1 is secreted by immune cells like macrophages, monocytes and dendritic cells through leaderless secretory pathway. Activated macrophages and monocytes secrete HMGB1. The mechanism of inflammation and damage is binding to TLR4, which mediates HMGB1-dependent activation of macrophage cytokine release. Treatment includes antibodies that neutralize HMGB1 protects against damage and tissue injury during arthritis, colitis, ischemia, sepsis, endotoxemia, and systemic lupus erythematosus. The molecules developed by Companies in Preclinical and Discovery stages are 5 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Furthermore, this report also reviews key players involved in High Mobility Group Protein Box-1 (HMGB1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Affibody AB
Bio3 Research S.r.l
Evec, Inc.
Ribomic Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll